The H1 Data Preservation Project South, D M; Steder, M
Journal of physics. Conference series,
01/2012, Letnik:
396, Številka:
6
Journal Article
Recenzirano
Odprti dostop
The H1 data preservation project was started in 2009 as part of the global data preservation initiative in high-energy physics, DPHEP. In order to retain the full potential for future improvements, ...the H1 Collaboration aims for level 4 of the DPHEP recommendations, which requires the full simulation and reconstruction chain as well as the data to be preserved for future analysis. A major goal of the H1 project is therefore to provide secure, long-lived and validated access to the H1 data and analysis software, which is realised in collaboration with DESY-IT using virtualisation techniques. By implementing such a system, it is hoped that the lifetime of the unique ep collision data from HERA will be extended, providing the possibility for novel analysis in the future. The preservation of the data and software is performed alongside a consolidation programme of digital and non-digital documentation, some of which dates back to the early 1980s. A new organisational model of the H1 Collaboration, reflecting the change to the long term phase, is to be adopted in July 2012.
Data preservation in High Energy Physics Kogler, R; South, D M; Steder, M
Journal of physics. Conference series,
01/2012, Letnik:
368, Številka:
1
Journal Article
Recenzirano
Odprti dostop
Data from high-energy physics experiments are collected with significant financial and human effort and are mostly unique. However, until recently no coherent strategy existed for data preservation ...and re-use, and many important and complex data sets have simply been lost. While the current focus is on the LHC at CERN, in the current period several important and unique experimental programs at other facilities are coming to an end, including those at HERA, b-factories and the Tevatron. To address this issue, an inter-experimental study group on HEP data preservation and long-term analysis (DPHEP) was convened at the end of 2008. The group now aims to publish a full and detailed review of the present status of data preservation in high energy physics. This contribution summarises the results of the DPHEP study group, describing the challenges of data preservation in high energy physics and the group's first conclusions and recommendations. The physics motivation for data preservation, generic computing and preservation models, technological expectations and governance aspects at local and international levels are examined.
Summary Background Preoperative chemoradiotherapy with infusional fluorouracil, total mesorectal excision surgery, and postoperative chemotherapy with fluorouracil was established by the German ...CAO/ARO/AIO-94 trial as a standard combined modality treatment for locally advanced rectal cancer. Here we compare the previously established regimen with an investigational regimen in which oxaliplatin was added to both preoperative chemoradiotherapy and postoperative chemotherapy. Methods In this multicentre, open-label, randomised, phase 3 study we randomly assigned patients with rectal adenocarcinoma, clinically staged as cT3–4 or any node-positive disease, to two groups: a control group receiving standard fluorouracil-based combined modality treatment, consisting of preoperative radiotherapy of 50·4 Gy in 28 fractions plus infusional fluorouracil (1000 mg/m2 on days 1–5 and 29–33), followed by surgery and four cycles of bolus fluorouracil (500 mg/m2 on days 1–5 and 29); or to an investigational group receiving preoperative radiotherapy of 50·4 Gy in 28 fractions plus infusional fluorouracil (250 mg/m2 on days 1–14 and 22–35) and oxaliplatin (50 mg/m2 on days 1, 8, 22, and 29), followed by surgery and eight cycles of oxaliplatin (100 mg/m2 on days 1 and 15), leucovorin (400 mg/m2 on days 1 and 15), and infusional fluorouracil (2400 mg/m2 on days 1–2 and 15–16). Randomisation was done with computer-generated block-randomisation codes stratified by centre, clinical T category (cT1–3 vs cT4), and clinical N category (cN0 vs cN1–2) without masking. The primary endpoint was disease-free survival, defined as the time between randomisation and non-radical surgery of the primary tumour (R2 resection), locoregional recurrence after R0/1 resection, metastatic disease or progression, or death from any cause, whichever occurred first. Survival and cumulative incidence of recurrence analyses followed the intention-to-treat principle; toxicity analyses included all patients treated. Enrolment of patients in this trial is completed and follow-up is ongoing. This study is registered with ClinicalTrials.gov , number NCT00349076. Findings Of the 1265 patients initially enrolled, 1236 were assessable (613 in the investigational group and 623 in the control group). With a median follow-up of 50 months (IQR 38–61), disease-free survival at 3 years was 75·9% (95% CI 72·4–79·5) in the investigational group and 71·2% (95% CI 67·6–74·9) in the control group (hazard ratio HR 0·79, 95% CI 0·64–0·98; p=0·03). Preoperative grade 3–4 toxic effects occurred in 144 (24%) of 607 patients who actually received fluorouracil and oxaliplatin during chemoradiotherapy and in 128 (20%) of 625 patients who actually received fluorouracil chemoradiotherapy. Of 445 patients who actually received adjuvant fluorouracil and leucovorin and oxaliplatin, 158 (36%) had grade 3–4 toxic effects, as did 170 (36%) of 470 patients who actually received adjuvant fluorouracil. Late grade 3–4 adverse events in patients who received protocol-specified preoperative and postoperative treatment occurred in 112 (25%) of 445 patients in the investigational group, and in 100 (21%) of 470 patients in the control group. Interpretation Adding oxaliplatin to fluorouracil-based neoadjuvant chemoradiotherapy and adjuvant chemotherapy (at the doses and intensities used in this trial) significantly improved disease-free survival of patients with clinically staged cT3–4 or cN1–2 rectal cancer compared with our former fluorouracil-based combined modality regimen (based on CAO/ARO/AIO-94). The regimen established by CAO/ARO/AIO-04 can be deemed a new treatment option for patients with locally advanced rectal cancer. Funding German Cancer Aid (Deutsche Krebshilfe).
(ProQuest: ... denotes formulae and/or non-USASCII text omitted; see image).A combination is presented of all inclusive deep inelastic cross sections previously published by the H1 and ZEUS ...collaborations at HERA for neutral and charged current ... scattering for zero beam polarisation. The data were taken at proton beam energies of 920, 820, 575 and 460 GeV and an electron beam energy of 27.5 GeV. The data correspond to an integrated luminosity of about 1 fb... and span six orders of magnitude in negative four-momentum-transfer squared, ..., and Bjorken x. The correlations of the systematic uncertainties were evaluated and taken into account for the combination. The combined cross sections were input to QCD analyses at leading order, next-to-leading order and at next-to-next-to-leading order, providing a new set of parton distribution functions, called HERAPDF2.0. In addition to the experimental uncertainties, model and parameterisation uncertainties were assessed for these parton distribution functions. Variants of HERAPDF2.0 with an alternative gluon parameterisation, HERAPDF2.0AG, and using fixed-flavour-number schemes, HERAPDF2.0FF, are presented. The analysis was extended by including HERA data on charm and jet production, resulting in the variant HERAPDF2.0Jets. The inclusion of jet-production cross sections made a simultaneous determination of these parton distributions and the strong coupling constant possible, resulting in ... An extraction of ... and results on electroweak unification and scaling violations are also presented.
The cross section for ee+ e- → π+ π- J/ψ between 3.8 and 5.5 GeV is measured with a 967 fb(-1) data sample collected by the Belle detector at or near the Υ(nS) (n = 1,2,…,5) resonances. The Y(4260) ...state is observed, and its resonance parameters are determined. In addition, an excess of π+ π- J/ψ production around 4 GeV is observed. This feature can be described by a Breit-Wigner parametrization with properties that are consistent with the Y(4008) state that was previously reported by Belle. In a study of Y(4260) → π+ π- J/ψ decays, a structure is observed in the M(π(±)J/ψ) mass spectrum with 5.2σ significance, with mass M = (3894.5 ± 6.6 ± 4.5) MeV/c2 and width Γ = (63 ± 24 ± 26) MeV/c2, where the errors are statistical and systematic, respectively. This structure can be interpreted as a new charged charmoniumlike state.
A combination is presented of all inclusive deep inelastic cross sections previously published by the H1 and ZEUS collaborations at HERA for neutral and charged current $e^{\pm}p$ scattering for zero ...beam polarisation. The data were taken at proton beam energies of 920, 820, 575 and 460 GeV and an electron beam energy of 27.5 GeV. The data correspond to an integrated luminosity of about 1 fb$^{-1}$ and span six orders of magnitude in negative four-momentum-transfer squared, $Q^2$, and Bjorken $x$. The correlations of the systematic uncertainties were evaluated and taken into account for the combination. The combined cross sections were input to QCD analyses at leading order, next-to-leading order and at next-to-next-to-leading order, providing a new set of parton distribution functions, called HERAPDF2.0. In addition to the experimental uncertainties, model and parameterisation uncertainties were assessed for these parton distribution functions. Variants of HERAPDF2.0 with an alternative gluon parameterisation, HERAPDF2.0AG, and using fixed-flavour-number schemes, HERAPDF2.0FF, are presented. The analysis was extended by including HERA data on charm and jet production, resulting in the variant HERAPDF2.0Jets. The inclusion of jet-production cross sections made a simultaneous determination of these parton distributions and the strong coupling constant possible, resulting in $\alpha_s(M_Z)=0.1183 \pm 0.0009 {\rm(exp)} \pm 0.0005{\rm (model/parameterisation)} \pm 0.0012{\rm (hadronisation)} ^{+0.0037}_{-0.0030}{\rm (scale)}$. An extraction of $xF_3^{\gamma Z}$ and results on electroweak unification and scaling violations are also presented.
Summary Background Preoperative chemoradiotherapy, total mesorectal excision surgery, and adjuvant chemotherapy with fluorouracil is the standard combined modality treatment for rectal cancer. With ...the aim of improving disease-free survival (DFS), this phase 3 study (CAO/ARO/AIO-04) integrated oxaliplatin into standard treatment. Methods This was a multicentre, open-label, randomised, phase 3 study in patients with histologically proven carcinoma of the rectum with clinically staged T3–4 or any node-positive disease. Between July 25, 2006, and Feb 26, 2010, patients were randomly assigned to two groups: a control group receiving standard fluorouracil-based combined modality treatment, consisting of preoperative radiotherapy of 50·4 Gy plus infusional fluorouracil (1000 mg/m2 days 1–5 and 29–33), followed by surgery and four cycles of bolus fluorouracil (500 mg/m2 days 1–5 and 29; fluorouracil group); and an experimental group receiving preoperative radiotherapy of 50·4 Gy plus infusional fluorouracil (250 mg/m2 days 1–14 and 22–35) and oxaliplatin (50 mg/m2 days 1, 8, 22, and 29), followed by surgery and eight cycles of adjuvant chemotherapy with oxaliplatin (100 mg/m2 days 1 and 15), leucovorin (400 mg/m2 days 1 and 15), and infusional fluorouracil (2400 mg/m2 days 1–2 and 15–16; fluorouracil plus oxaliplatin group). Randomisation was done with computer-generated block-randomisation codes stratified by centre, clinical T category (cT1–4 vs cT4), and clinical N category (cN0 vs cN1–2) without masking. DFS is the primary endpoint. Secondary endpoints, including toxicity, compliance, and histopathological response are reported here. Safety and compliance analyses included patients as treated, efficacy endpoints were analysed according to the intention-to-treat principle. This study is registered with ClinicalTrials.gov , number NCT00349076. Findings Of the 1265 patients initially enrolled, 1236 were evaluable (613 in the fluorouracil plus oxaliplatin group and 623 in the fluorouracil group). Preoperative grade 3–4 toxic effects occurred in 140 (23%) of 606 patients who actually received fluorouracil and oxaliplatin during chemoradiotherapy and in 127 (20%) of 624 patients who actually received fluorouracil chemoradiotherapy. Grade 3–4 diarrhoea was more common in those who received fluorouracil and oxaliplatin during chemoradiotherapy than in those who received fluorouracil during chemoradiotherapy (73 patients 12% vs 52 patients 8%), as was grade 3–4 nausea or vomiting (23 4% vs nine 1%). 516 (85%) of the 606 patients who received fluorouracil and oxaliplatin-based chemoradiotherapy had the full dose of chemotherapy, and 571 (94%) had the full dose of radiotherapy; as did 495 (79%) and 601 (96%) of 624 patients who received fluorouracil-based chemoradiotherapy, respectively. A pathological complete response was achieved in 103 (17%) of 591 patients who underwent surgery in the fluorouracil and oxaliplatin group and in 81 (13%) of 606 patients who underwent surgery in the fluorouracil group (odds ratio 1·40, 95% CI 1·02–1·92; p=0·038). In the fluorouracil and oxaliplatin group, 352 (81%) of 435 patients who began adjuvant chemotherapy completed all cycles (with or without dose reduction), as did 386 (83%) of 463 patients in the fluorouracil group. Interpretation Inclusion of oxaliplatin into modified fluorouracil-based combined modality treatment was feasible and led to more patients achieving a pathological complete response than did standard treatment. Longer follow-up is needed to assess DFS. Funding German Cancer Aid (Deutsche Krebshilfe).
We report here measurement of the cross section of e+e- → π+π-ψ ( 2S ) between 4.0 and 5.5 GeV, based on an analysis of initial state radiation events in a 980fb-1 data sample recorded with the Belle ...detector. The properties of the Y ( 4360 ) and Y ( 4660 ) states are determined. Fitting the mass spectrum of π+π-ψ ( 2S ) with two coherent Breit-Wigner functions, we discover two solutions with identical mass and width but different couplings to electron-positron pairs: MY ( 4360 ) = ( 4347±6±3 ) MeV / c2 , Γ Y ( 4360 ) = ( 103±9±5 ) MeV , MY ( 4660 ) = ( 4652±10±8 ) MeV / c2 , Γ Y ( 4660 ) = ( 68±11±1 ) MeV ; and B Y ( 4360 ) → π+π-ψ ( 2S ) · Γ Y ( 4360 ) e+e-= ( 10.9±0.6±0.7 ) eV and B Y ( 4660 ) → π+π-ψ ( 2S ) · Γ Y ( 4660 ) e+e-= ( 8.1±1.1±0.5 ) eV for one solution; or B Y ( 4360 ) → π+π-ψ ( 2S ) · Γ Y ( 4360 ) e+e-= ( 9.2±0.6±0.6 ) eV and B Y ( 4660 ) → π+π=ψ ( 2S ) · Γ Y ( 4660 ) e+e-= ( 2.0±0.3±0.2 ) eV for the other. Here, the first errors are statistical and the second systematic. Evidence for a charged charmoniumlike structure at 4.05GeV / c2 is observed in the π±ψ ( 2S ) intermediate state in the Y ( 4360 ) decays. decays.
The first measurement of lepton-jet momentum imbalance and azimuthal correlation in lepton-proton scattering at high momentum transfer is presented. These data, taken with the H1 detector at HERA, ...are corrected for detector effects using an unbinned machine learning algorithm (multifold), which considers eight observables simultaneously in this first application. The unfolded cross sections are compared with calculations performed within the context of collinear or transverse-momentum-dependent factorization in quantum chromodynamics as well as Monte Carlo event generators.
Measurements of open charm and beauty production cross sections in deep inelastic
ep
scattering at HERA from the H1 and ZEUS Collaborations are combined. Reduced cross sections are obtained in the ...kinematic range of negative four-momentum transfer squared of the photon
2.5
GeV
2
≤
Q
2
≤
2000
GeV
2
and Bjorken scaling variable
3
·
10
-
5
≤
x
Bj
≤
5
·
10
-
2
. The combination method accounts for the correlations of the statistical and systematic uncertainties among the different datasets. Perturbative QCD calculations are compared to the combined data. A next-to-leading order QCD analysis is performed using these data together with the combined inclusive deep inelastic scattering cross sections from HERA. The running charm- and beauty-quark masses are determined as
m
c
(
m
c
)
=
1
.
290
-
0.041
+
0.046
(
exp
/
fit
)
-
0.014
+
0.062
(
model
)
-
0.031
+
0.003
(
parameterisation
)
GeV and
m
b
(
m
b
)
=
4
.
049
-
0.109
+
0.104
(
exp
/
fit
)
-
0.032
+
0.090
(
model
)
-
0.031
+
0.001
(
parameterisation
)
GeV
.
PDF
